Prevalence of Inappropriate Prescriptions and Omitted Therapies in Hospitalized Elderly: STOPP/START Criteria Analysis
NCT ID: NCT07202962
Last Updated: 2025-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2024-07-17
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inappropriate Prescribing in the Elderly
NCT06760728
Prevention of Potentially Inappropriate Prescribing in Late Life Using Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) and Screening Tool to Alert Doctors to Right Treatment (START) Criteria
NCT00915824
Multidisciplinary Program "Optimization of Drug Prescription" : Impact on the Quality of Drug Prescription in Hospitalized Elderly Patients
NCT01947270
Intervention to Improve Prescribing in Elderly Patients
NCT02712268
Potentially Inappropriate Prescription Associated to Multimorbidity
NCT02830425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
medication review and deprescribing
The study protocol includes the following assessments:
* T0: first data collection upon admission to the ward;
* T1 assessment: pharmacological review at discharge. Subjects who meet all study eligibility criteria will come consecutively enrolled in the study during admission to the department (T0).
By consulting the electronic health record, interviewing patients and family members and personal documentation, the following data will be collected:
* Remote and immediate pathological history;
* Family and social history;
* Home therapy;
* BRIEF-MPI. Home therapy and therapy suggested at discharge will be compared with the STOPPandSTART criteria to evaluate the prevalence of potential therapies inappropriate and to study possible interactions and contraindications pharmacological and for reporting possible adverse reactions to drugs. The prevalence and possible prevalence of each individual STOPPandSTART criterion will be assessed association with other variables of interest.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently undergoing pharmacological treatment at the time of admission.
Exclusion Criteria
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regione del Veneto - AULSS n. 7 Pedemontana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luca Pellizzari
Director of Geriatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luca Pellizzari Dr. Pellizzari, DR
Role: PRINCIPAL_INVESTIGATOR
Regione del Veneto - AULSS n. 7 Pedemontana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regione del Veneto - AULSS n. 7 Pedemontana
Santorso, Vicenza, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1239
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.